Determination of New Biomarkers of Septic Arthritis by Surface-Enhanced Laser Desorption/Ionization Time-Of-Flight (SELDI-TOF)

Caractérisation de Nouveaux Biomarqueurs de l'Arthrite Septique Par Technique SELDI-TOF

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01010165

Acronym

NOUBASST

Enrollment

Registered

2009-11-09

Start date

2009-10-31

Completion date

2012-10-31

Last updated

2012-10-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Arthritis

Keywords

acute arthritis, bacteria, crystal arthritis, proteomic, SELDI-TOF

Brief summary

Septic arthritis is a frequent, potentially disabling and/or life-threatening disease. To diagnose a septic arthritis is a complex procedure, first because of numerous differential diagnoses (such as crystal arthritis), second because of poor sensitivity of initial gram staining (for example after untimely antibiotic therapy). This protocol will use SELDI-TOF as a tool to analyse joint fluid of patients with various acute, polymorphonuclear-rich arthritis, as to determine specific and sensitive new biomarkers of a septic origin. Such biomarkers will allow rapid diagnosis of septic arthritis in the first hours of admission.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* acute arthritis (onset not more than 7 days ago) * joint fluid leukocyte count : more than 2000/mm3, more than 50% polymorphonuclear

Exclusion criteria

* none (apart from unability to accept inclusion)

Countries

France

Outcome results